Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

NCT03392389 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
124
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ModernaTX, Inc.